Irbepress

Irbesartan, the active ingredient in Irbepress, is an angiotensin II receptor blocker (ARB) formulated as oral tablets. It is used to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy, primarily in adult populations.

GNH USA supplies Irbepress as a licensed, GDP‑compliant product, providing reliable international sourcing for hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets, and ensuring timely delivery to meet patient care needs globally.

Irbesartan is an angiotensin II receptor blocker indicated for conditions related to the renin‑angiotensin system. - Hypertension: reduces systolic and diastolic blood pressure in adults. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Proteinuria in diabetic kidney disease: decreases urinary protein excretion, helping preserve renal function.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate head pain. - Fatigue: feeling unusually tired. - Hyperkalaemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or airway. - Acute renal failure: sudden decrease in kidney function. - Severe hypotension: markedly low blood pressure causing faintness.

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and eGFR periodically. - Serum potassium monitoring: check for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Volume depletion: use caution in patients who are dehydrated or on diuretics. - Hypersensitivity: avoid in individuals with known allergy to irbesartan or other ARBs. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original pack, protect from moisture.

Irbesartan may interact with several medicines; awareness of the interaction level is essential. Major Interactions (Avoid): - Concomitant use with aliskiren in patients with diabetes. - Combined therapy with ACE inhibitors or other ARBs. - Potassium‑sparing diuretics or potassium supplements. Moderate Interactions (Monitor Closely): - NSAIDs: may blunt the antihypertensive response. - Lithium: may increase lithium serum concentrations, requiring level monitoring.